Study Evaluating MAC-321 in Colorectal Cancer

Summary

Assess the clinical activity of MAC-321 administered IV as a second-line or third-line antineoplastic agent to subjects with advanced colorectal cancer. Clinical activity will be assessed by determining the percentage of subjects exhibiting an objective response (complete plus partial responses). Tumor response will be assessed following modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.

Timeline

Start

—

Primary completion

2004-02

Completion

2004-02

Drugs

Indications